Monogram Technologies stated its innovations combine 3D printing, advanced maker vision, AI, and next-generation robotics.|Source: Monogram TechnologiesZimmer Biomet Holdings, Inc.
today revealed that it is getting Monogram Technologies Inc., an orthopedic robotics company.
The worldwide medical technology designer will get all exceptional shares of Monogram for $4.04 a share, totaling an equity worth of $177 million and a business worth of $168 million.“& ldquo; Monogram & rsquo; s technology is a significant leap forward, demonstrating our dedication to becoming the boldest and broadest innovator in surgical robotics and navigation,” & rdquo; stated Ivan Tornos, the chairman, president, and CEO of Zimmer Biomet.
“& ldquo; Upon closing, our customer-centric portfolio will include the most detailed and versatile technology environment to support the varying preferences of a large selection of surgeons —-- now and into the future.”“& rdquo; & ldquo; With Monogram & rsquo; s proprietary innovation, Zimmer Biomet has the prospective to become the very first company to provide fully autonomous abilities and redefine both the requirement of care and the future of orthopedic surgery,” & rdquo; he continued.The respective boards of directors of Zimmer Biomet and Monogram all authorized the proposed transaction.
Zimmer Biomet, which has workplaces in Montpelier, France, and Warsaw, Ind., offers its flagship ROSA platform.
ROSA, which just recently expanded into shoulder replacement, has four applications, including the knee.Zimmer Biomet to integrate Monogram tech into ROSAZimmer Biomet stated it anticipates Monogram Technologies’ & rsquo; semi-and fully autonomous robotic technologies to include new and separated abilities to expand its own surgical robot.Monogram has actually established a CT-based, semi-autonomous, AI-navigated total knee arthroplasty (TKA) robotic technology.
It made FDA 510(k) clearance in March 2025.
The Austin, Texas-based business stated it expects to advertise the mBô& ocirc; s innovation with Zimmer Biomet implants in early 2027.
In addition, Monogram is establishing a totally self-governing variation of the mBô& ocirc; s system.
It asserted that the technology could considerably increase safety, performance, and results, in addition to address applications beyond TKA.“& ldquo; Since our inception, we have been singularly concentrated on advancing orthopedic robotics with technology created to securely, efficiently, and properly support cosmetic surgeons with overall knee arthroplasty,” & rdquo; stated Benjamin Sexson, CEO of Monogram.
“& ldquo; We are delighted by the chance to include our technology to Zimmer Biomet’& rsquo; s leading portfolio of surgical robotics, navigation services, and trusted implants and to gain from their deep industry knowledge and international scale.”& rdquo; Zimmer Biomet said it anticipates the acquisition to add to profits growth in 2027 and beyond.
The company noted that mBô& ocirc; s will aid robotic knee adoption in the U.S., increase its market show a broader item variety, and expand its international knee offerings.Zimmer Biomet to broaden ROSA applicationsThe proposed deal expands Zimmer Biomet’& rsquo; s extensive suite of orthopedic robotics.
This provides it access to systems and analytics to attend to the needs of surgeons pre-, intra-, and post-operatively.
The company stated its portfolio includes: Imageless robotics through its ROSA platformA licensed CT-based portable robotMixed truth navigationAI-based surgical navigationA path to sophisticated semi- and totally self-governing robotics capabilities.Zimmer Biomet forecasted that it will have the ability to attend to the diverse choices of cosmetic surgeons globally and multiple styles of surgical techniques.
This includes CT and non-CT, robotic and non-robotic, and manual, surgeon-centered techniques, or semi- or totally autonomous technologies.The ROSA platform is rapidly approaching 2,000 setups worldwide, the company claimed.
Zimmer Biomet stated it is devoted to continuing to advance the ROSA platform and is investing in a robust R&D pipeline featuring numerous new items and software applications anticipated in between now and 2027.
This includes ROSA Knee with OptimiZe, which has been sent to the FDA, and 510(k) clearance is expected later this year, along with ROSA Posterior Hip and the full industrial launch of ROSA Shoulder.
Zimmer Biomet has likewise worked with THINK Surgical Inc.
on integrating the Persona system with the TMINI surgical robot.Save now with early riser discountThe post Zimmer Biomet to acquire Monogram Technologies for $177M appeared initially on The Robot Report.